[Multicentric clinical proof of a new oral antidiabetic glisoxepide (BS 4231). 3. Results of tolerance tests].
D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001381:Azepines / Q000009:adverse effects / Q000627:therapeutic use*; D001786:Blood Glucose; D056486:Chemical and Drug Induced Liver Injury; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004341:Drug Evaluation; D004342:Drug Hypersensitivity; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000139:chemically induced; D010080:Oxazoles / Q000009:adverse effects / Q000627:therapeutic use*; D010292:Paresthesia / Q000139:chemically induced; D010787:Photosensitivity Disorders / Q000139:chemically induced; D013453:Sulfonylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D001381:Azepines; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D010080:Oxazoles; D013453:Sulfonylurea Compounds; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase
Multizentrische klinische Prüfung des neuen oralen Antidiabetikums Glisoxepid (BS 4231). 3. Ergebnisse der Verträglichkeitsprüfung